Background

India currently has 66 million people with diabetes, and this number is projected to rise to 101 million by 2030 [1]. In 2016, diabetes accounted for 10.4 million disability-adjusted life years (DALYs) in India, an increase of 175% over 1990. Diabetes also contributes to DALYs from other conditions. For example, diabetes accounted for over 50% of the global increase in chronic kidney disease DALYs during this period [2]. The largest increase in diabetes DALYs was noted in rural communities in India, where 65% of the population currently resides, [3] posing challenges for India’s fragile health system [4].

A shortage of primary care workforce, lack of an efficient community-based screening program, and provision of guideline-based clinical care undermine the efforts to manage diabetes in India. Health and wellness centres (HWCs) are central to the Indian National Health Policy’s provision of comprehensive primary health care (PHC) [5]. The government plans to establish 150,000 HWCs by 2022. Innovative delivery methods, such as task-shifting and use of technology, along with improved access to medicines and diagnostics, have the potential to increase access to quality guideline-based healthcare. Task-shifting, where front-line, non-physician health workers (such as the accredited social health activists [ASHA], selected from amongst the local female residents of the village) are delegated some of the tasks traditionally performed by physicians, has been shown to improve health outcomes and processes of care [6]. Deployed primarily for maternal and child health services, they are being increasingly used to identify and manage other health conditions, including non-communicable diseases (NCDs) [7]. The potential of digital technology to improve the performance of the health workforce by providing them prompt access to job-aids and clinical decision support system (CDSS) has been increasingly recognized [8]. Various systematic reviews have outlined the role of CDSS to deliver appropriate healthcare [9, 10], but the evidence for their effectiveness and feasibility in primary healthcare is still fragmented [11].

Methods

Objectives

The IMPACT diabetes is a proof of concept randomised trial that aims to develop and evaluate a bespoke diabetes management program that empowers ASHA and PHC doctors through a mobile platform–based CDSS embedded in the public healthcare system to improve the identification and management of diabetes. The primary objective of the study is to evaluate the effectiveness of the extended care intervention by observing the difference in HbA1c (glycosylated hemoglobin) measured at baseline and end-line. The main secondary objective is to ascertain the acceptability and feasibility of the proposed intervention by conducting qualitative interviews of physicians, ASHAs, and community members.

Overall design and methods

Development of the CDSS

The George Institute for Global Health has developed Systematic Medical Appraisal Referral, and Treatment (SMARThealth), a mobile-based cardiovascular disease (CVD) referral and management platform for use in the primary healthcare system. The process of development and field-testing of the SMARThealth CVD has been published elsewhere [12]. Briefly, the package consists of a 7-inch tablet running android operating system with the CDSS application, training and resource support for ASHA and primary care physicians, shared electronic record functionality using open medical record system (open MRS), a prompt system for referral and follow-up, ensuring medication supply, and remuneration for the ASHAs. Data uploads occur whenever a network connection is available. ASHAs make electronic referrals to the PHC physicians and get alerts after the physician has confirmed the diagnosis and prepared a management plan.

The platform was expanded to integrate assessment and management protocols for diabetes and its complications. The process of CDSS development was as follows: we developed a plain language algorithm for screening and management of diabetes based on the review of the current Indian [13] and international guidelines [14, 15], followed by a three-step process for the validation of the algorithm. Firstly, a group of expert physicians reviewed the plain language algorithm to assess the appropriateness of pharmacological and lifestyle recommendations. The algorithm was then converted into a statistical and programming code. In the second step, a researcher not involved with the algorithm development was given the plain language algorithm summary along with mock input data from 200 patients. Programming modifications in the statistical code were made, where necessary. Finally, the plain language rules were built as a java-based application. De-identified data from a large cross-sectional study (approximately 10,000 patients) was run using both the statistical and the programming codes. Correlation for each of the calculated variables between those generated from the programming code and the statistical code was assessed. Changes were made in the application until 100% consistency was obtained between both the outputs. The final programme code was integrated with the existing SMARThealth platform. The English language strings were translated into local languages (Telugu and Hindi) for field-testing the integrated platform.

Study design and sites

The study is a population-based, pragmatic cluster–randomized trial conducted in the public healthcare systems in two locations: rural areas of Guntur district of Andhra Pradesh and peri-urban centres in Rohtak district in Haryana. A total of 8 PHC facilities were selected in the two study areas (Fig. 1) in consultation with respective district health authorities. Within each PHC, two villages (in case of Guntur) or peri-urban areas (in case of Rohtak) were randomly selected from the list of 35 villages/areas.

Fig. 1
figure 1

Sampling technique and randomization scheme for the study. PHC — primary health centres; ASHAs — accredited social health activists

Eligibility and recruitment

Within each village/area, one ASHA was assigned to screen approximately 100 community members over the age of 30 years. Participants were excluded if they had any physical illness that prevented follow-up, any intellectual disability that prevents them from following instructions or responding to the questionnaire, or if the participant is unlikely to stay in the community for the duration of the study. Pregnant women were also excluded. ASHAs screened the participants using capillary blood glucose testing (Fig. 2) in their households during their routine health promotion work. Glycosylated hemoglobin (HbA1c) test was performed on participants with random blood glucose (RBG) ≥ 200 mg/dL or fasting blood glucose (FBG) >126 mg/dL), as per the Research Society for the Study of Diabetes in India (RSSDI) clinical practice guidelines [13]. The HbA1c testing was performed by an accredited laboratory in compliance with National Glycohemoglobin Standardization Programme.

Fig. 2
figure 2

Illustration of the intervention design. PHC — primary health centres; ASHAs — accredited social health activists; RBG — random blood glucose; FBG — fasting blood glucose; HbA1c — glycosylated haemoglobin; CDSS — clinical decision support system

Intervention

Study intervention, information dissemination strategies, and recruitment methods were developed in consultation with the local community members, ASHAs, and healthcare professionals. Subjects with elevated blood glucose levels were referred to the participating PHC physicians. Using the SMARThealth CDSS, the physicians prescribe guideline-based medications from the essential medicine list and provide evidence-based recommendations on blood glucose and blood pressure (BP) monitoring, and lifestyle changes (Fig. 3). After physician consultation, ASHAs receive system–generated alerts on their devices about the follow-up schedules. ASHAs repeat the lifestyle recommendation and emphasize the need for treatment adherence and regular follow-up during household follow-up visits. Table 1 highlights the difference between the care facilities provided to the participants in the control and intervention areas. Participants with normal HbA1c received lifestyle modification recommendations from ASHAs and were advised a follow-up blood glucose testing after 12 months. Those found to have normal capillary blood glucose values were advised to get follow-up testing after 3 years.

Fig. 3
figure 3

Nutritional, pharmacological, and behavioural risk factor management recommendations provided by PHC physicians

Table 1 Summary of the differences between the care facilities

Training

A training program was developed and provided to ASHAs and PHC physicians on the use of SMARThealth platform. The training manual included modules on screening and management for diabetes, its complications and CVD risk; the use of the mobile application, screening methodology, interpretation of the decision support output, context-specific management advice, and blood pressure and capillary blood sugar measurement. The training material was developed in Hindi and Telugu for use in Rohtak and Guntur respectively. The duration of the first spell of training was 5 days, followed by a minimum of 3 days of field practice. Booster training was provided after 2 weeks. PHC physician training involved one-on-one guidance in the use of the electronic data collected by the ASHAs, and interpretation of the CDSS output for management decisions.

Measurements and confirmation of diagnosis

The ASHA collected demographic and clinical data and measured height, weight, BP, and capillary blood glucose for each participant. We used A&D UA-767 Plus Bluetooth-enabled digital BP monitors (A&D Limited, Tokyo, Japan). Three readings were taken 2 to 3 min apart, and the average of the second and the third reading was taken as the final BP for each participant [16]. Abbott FreeStyle Optium Neo (Abbott Diabetes Care Inc, CA, USA) monitors were used for the measurement of capillary blood glucose.

Hypertension is defined as systolic blood pressure (SBP) of ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg (20) and/or self-reported use of antihypertensive drugs. As per the RSSDI clinical practice guidelines, diabetes is defined as capillary RBG levels of ≥200 mg/dL or self-reported use of glucose-lowering drugs [13]. For those with RBG of 140–199 mg/dL, a capillary FBG test was done at home within 1 week of their RBG test, and a value >126 mg/dL was required for the diagnosis of diabetes. Participants with raised blood glucose levels underwent HbA1c testing. World Health Organization/International Society of Hypertension (WHO/ISH) low information prediction chart are used to measure the 10-year risk of a cardiovascular event (myocardial infarction or stroke) [17].

PHC visit and ASHA follow-up

In the intervention arm, a laboratory technician measured the BP and RBG of the participants at the PHC. The physicians review lifestyle advice given by ASHAs, and provide pharmacological advice with the aid of the SMARThealth CDSS. The ASHAs can track the visit and do follow-up visits to record BP, blood glucose, and adherence to prescribed medications using the Morisky medication adherence scale [18]. If any medical care is received outside the PHC (due to prevalent practice), the ASHA records the details of the type of health facility visited and reasons for not visiting PHC.

End of the study

HbA1C test will be repeated after 9 months. Focus group discussions (FGD) and semi-structured interviews of physicians, ASHAs, and community members will be conducted to ascertain the acceptability and implementation feasibility of the intervention. Semi-structured interviews and FGD guidelines will be developed based on the review of the literature and research questions. Interviews will be conducted by researchers experienced in these field settings.

Outcomes measures and analyses

Quantitative measures

The primary outcome measure will be the difference in the proportion of participants with diabetes showing a 0.5% reduction in HBA1c [19]. An a priori power calculation indicated that 10 participants with diabetes are needed per cluster to detect a 20% additional reduction in the intervention group as compared with the control group. Using two-sided tests at a significance level of 5%, and intraclass correlation coefficient (ICC) of 0.03 (based on our previous work [20], we can achieve a statistical power of 80%. Secondary outcome measures include proportions of individuals visiting a physician and adherence to blood glucose–lowering medications.

Qualitative measures

The acceptability and feasibility of the intervention will be ascertained through the understanding of (i) ASHAs’ and physicians’ experience with the intervention, (ii) impact of CDSS on staff’s usual work routines and knowledge, and (iii) patient satisfaction with the treatment and management recommendations.

Analysis

Inferential statistical analysis will be performed on an intention-to-treat basis. Student’s t test and one-way analysis of variance (ANOVA) will be applied to compare continuous variables, and the chi-squared test will be used to compare categorical variables. Due to the clustered study design, the primary outcome will be assessed using a generalized linear mixed regression model. p values of less than 0.05 will be considered statistically significant. Within-trial economic evaluation will be conducted to evaluate the incremental costs per quality-adjusted life-years gained and cost per 0.5% reduction in HbA1c. The intervention cost will be based on salaries, training, equipment, and other costs incurred with the implementation of the intervention.

All interviews and FGDs will be digitally recorded, professionally transcribed, and translated to English. We will verify 10% of the randomly selected transcriptions against the recordings for quality control. Thematic content analysis of the transcriptions and field notes will be performed using NVivo software (version 11). Two members from the research team will code transcripts based on the following deductive (a priori) codes: (i) facilitators and barriers for quality NCDs and diabetes management in resource-poor settings, (ii) satisfaction with the training, (iii) perceived usefulness and difficulties of the CDSS, (iv) perception on the behaviour change intervention package, (v) impact on work routines, and (vi) ASHAs’, doctors’, and participants’ satisfaction. Significant inductive (emerging) codes will also be identified. Coded items will be grouped into distinct themes, drawing on the methods outlined by Patton [21]. The inter-coder reliability will be checked, and a Kappa-statistic will be calculated. A third qualitative researcher will adjudicate discrepancies.

Ethical considerations

Ethical approvals were obtained from the Institutional Ethics Committees of Centre for Chronic Disease Control, New Delhi (FWA00012746), and PGIMS, Rohtak, Haryana (IEC/18/524). All the study participants provided written informed consent.

Results

The recruitment was carried out between January and August 2019 in Guntur and between August 2019 and January 2020 in Rohtak. Table 2 present the baseline characteristics of the participants. A total of 1785 participants, 53.2% females and median, (inter-quartile range, (IQR)) age of 50 (40–61) years were screened. We achieved 100% completeness of data for all anthropometric, BP, and blood glucose measures (Table 2). ASHA screenings revealed that 27.8% of the screened participants had an elevated BP, 21.3% had elevated blood glucose, and 20.3% had a high 10-year CVD risk (Table 2).

Table 2 Participant baseline demographic characteristics, medical and family history, and metabolic characteristics

Figure 4 presents the self-reported diagnosis and treatment history of the participants with hypertension and diabetes. Half of the participants with hypertension and 43% of the participants with diabetes were newly diagnosed.

Fig. 4
figure 4

Self-reported diagnosis and treatment history of the participants with hypertension and diabetes

Discussion

The encouraging completion rates of anthropometric, BP, and blood glucose measures in this multicomponent health-system intervention embedded in routine primary care practice settings reiterates that with training and retraining, the ASHA are able to identify individuals with hypertension and diabetes, and can contribute to improving efficiency of service delivery [22]. While the ASHAs are used to completing a paper-based assessment checklist and motivate the community members to visit the community-based screening camps, the current intervention goes beyond and allows them to accurately identify those in need for referral using an automated electronic decision support system.

The effectiveness of the SMARThealth platform in linking community-based assessments to doctor level care has been tested in the areas of CVD and mental health [23, 24]. The addition of BP and blood glucose testing allowed expansion of the capability of the platform but also challenges the argument that ASHA cannot acquire such skills. The role of technological innovations is important in resource-poor settings of India, where the health system has been criticized for its unacceptably low quality and poor effectiveness [25]. Recent systematic reviews has shown that integration of mobile technology within the health system can overcome challenges related to service accessibility and treatment quality in primary care settings in India [10, 26, 27]. In a recent cluster randomised trial, Prabhakaran et al. found that electronic decision support for healthcare providers was not better than ‘enhanced usual care’ in management of blood pressure or diabetes in community [28]. Despite the null result, the trial showed that implementation of an mHealth intervention tool was feasible.

The baseline data provides us information about anthropometric and metabolic characteristics of the study subjects. Of note is the high proportion of undiagnosed cases of hypertension and diabetes in the community. Several national and state-level community-based studies have reported similar findings. A cross-sectional study of 5127 individuals in the state of Punjab revealed that 70% of the people with hypertension were undiagnosed or untreated [29]. Similarly, the Indian Council of Medical Research India Diabetes Study (n=57,117 in 14 states) found that 47.3% of participants with diabetes were previously undiagnosed [30]. These studies were done 6 to 10 years ago, and the proportion of untreated cases has remained unchanged despite the increasing awareness of NCDs, reinforcing the need to bring in a new approach.

A strength of the study is its pragmatic design that allows the utilization of existing care pathways in the Indian primary care systems. The existing workforce will implement this multicomponent intervention in the context of their current roles and responsibilities and during their routine health promotion work, obviating the need for additional household visits. The combination of quantitative and qualitative findings would help identify key components of the health system that might need strengthening for prevention and management of NCDs. Implementation in two geographies and health systems will provide information around the generalisability of the findings.

The study also has some limitations. The main purpose of this feasibility study is to obtain preliminary estimates (such as the variance of treatment effect) that can be used for planning a larger trial. Due to the limited sample size, our study may be underpowered to detect a true effect of the intervention. Secondly, because of the non-random selection of the participants, we would not be able to estimate the true prevalence of diabetes. However, based on the study objectives, we have chosen outcomes that are meaningful for routine practice.

In conclusion, the IMPACT diabetes study will provide evidence whether transfer of simple clinical procedures from physicians to non-physician health workers and judicious use of technology can be effectively deployed for managing diabetes and its complications in underserved communities. Findings of this study would feed into a larger trial that would provide information on process measures and the cost-effectiveness of this multicomponent intervention.